'True' fasting serum insulin level, insulin resistance syndrome and coronary artery disease

Adipose tissue is a powerful endocrine organ, which synthesizes significant amount of biologically active substances – adipokines. Due to adipokine dysfunction, a spectrum of diseases associated with obesity appears, namely, coronary artery disease, diabetes mellitus, hypertension and oncology. Hyperinsulinemia and insulin resistance play a significant role in pathogenesis of cardiometabolic complications in patients with obesity. They trigger a pathological cascade of reactions leading to cardiovascular diseases. Omentin-1 possesses anti-atherogenic action and it can modify peripheral effects of insulin. The aim of the study – to analyze changes in omentin-1 concentration and the condition of insulin resistance in patients with coronary artery disease and obesity during atorvastatin treatment. Materials and Methods. 55 patients with obesity were examined. They had general clinical examination; blood lipids, uric acid level and liver enzymes; glycated hemoglobin, glucose, insulin with the calculation of HOMA index and omentin-1 concentration was determined. Patients were divided into two groups: the group 1 – 20 patients with obesity, who did not suffer from CAD and did not take atorvastatin, and the group 2 – patients with CAD and obesity, who took atorvastatin. Determination of these indices was performed for patients of the group 2 in dynamics in 12 months. Results and Discussion. In the group of patients with CAD and obesity, who took atorvastatin, lipid levels were reliably lower, but levels of fasting glucose concentration, uric acid and liver enzymes were higher than in the patients who did not take the drug. Elevation of omentin-1 in blood serum was observed in 12 months in patients with CAD and obesity simultaneously with the increase in insulin level and the decrease in tissue sensitivity to it. Conclusions. Intake of atorvastatin by patients with coronary artery disease and obesity is accompanied by elevation of insulin concentration, intensification of insulin resistance and increase in omentin-1 level.

Download Full-text

Effect of postmenopausal status on insulin sensitivity in myanmar women

Asian Journal of Medical Sciences ◽

10.3126/ajms.v7i5.14750 ◽

2016 ◽

Vol 7 (5) ◽

pp. 36-41

Author(s):

Lwin Aye Thet ◽

Mya Thanda Sein ◽

Tint Swe Latt

Keyword(s):

Insulin Resistance ◽

Blood Glucose ◽

Insulin Sensitivity ◽

Serum Insulin ◽

Fasting Blood Glucose ◽

Insulin Level ◽

Enzyme Linked Immunosorbent Assay ◽

Serum Insulin Level ◽

Fasting Serum ◽

Postmenopausal Status

Background: Animal studies show that ovarian hormone deficiency is associated with development of insulin resistance. In women, the menopause transition marks the cessation of ovarian function and insulin sensitivity would be reduced in postmenopausal women.Aim and Objectives: This study aimed to evaluate the insulin sensitivity in Myanmar postmenopausal women compared to premenopausal womenMaterial and Methods: A cross sectional comparative study was undertaken in non obese, normal glucose tolerant post menopausal women (n=42, BMI (mean± SD) 21.3±2.8 kg/m2, age 52.6±4.4 years) and premenopausal women (n=33, BMI(mean± SD) 19.7±2.2 kg/m2, age32.7±4.9 years). Insulin sensitivity was assessed by homeostasis model assessment method of insulin resistance (HOMA-IR) based on fasting blood glucose and fasting serum insulin level. Blood glucose was determined by glucose oxidase method. Serum insulin was estimated by enzyme linked immunosorbent assay (ELISA).Results:No differences in fasting blood glucose level (Mean ±SD 4.87±0.51 vs. 4.76±0.63mmol/L), fasting serum insulin level [median and interquartile range (IQR) 8.1 (6.7-11.8) vs. 8.1(6.5-9.9) µ IU/ml] and HOMA-IR [median and IQR 1.7 (1.4-2.8) vs. 1.7 (1.2-2.2)] were found between premenopausal and postmenopausal women.Conclusion: Postmenopausal status has no effect on insulin sensitivity in postmenopausal women.Asian Journal of Medical Sciences Vol.7(5) 2016 36-41

Download Full-text